Latest News
MingMed Biotechnology presents QA102 Phase II trial data in intermediate AMD at ARVO 2026
6 May 2026 - Chinese biomedical company MingMed Biotechnology Co Ltd on Tuesday reported positive results from its Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD).Study results were presented ...
Alebund Pharmaceuticals completes AP301 Phase III clinical trial patient enrolment for hyperphosphataemia
6 May 2026 - Chinese biopharmaceutical company Alebund Pharmaceuticals Limited announced on Wednesday the completion of patient enrolment in the global Phase III pivotal multi-regional clinical trial (RESPOND-2, Study AP301-HP-03) of AP301, a novel f...
Lilly declares Q2 2026 dividend
5 May 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that its board of directors has approved a dividend of USD1.73 per share on its outstanding common stock for the second quarter of 2026.This amount is unchang...
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
5 May 2026 - US life sciences company Lunai Bioworks Inc (NASDAQ:LNAI) announced on Monday the completion of a USD20m preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the company's central nerv...
Neurocrine Biosciences survey shows significant burden of tardive dyskinesia on employment and education
5 May 2026 - US biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) on Monday announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go to schoo...